Type I IFN deficiency:an immunological characteristic of severe COVID-19 patients

作     者：Zhenling Wang Hailong Pan Boguang Jiang 

作者机构：State Key Laboratory of Biotherapy and Cancer CenterWest China HospitalSichuan University and Collaborative Innovation Center of BiotherapyChengdu 610041China Department of Quality ManagementChina National Biotec Group Company Limited100020 BeijingChina 

出 版 物：《Signal Transduction and Targeted Therapy》 (信号转导与靶向治疗（英文）)

年 卷 期：2020年第5卷第1期

页      面：812-813页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

基　　金：supported by the National Major Scientific and Technological Special Project for“Significant New Drugs Development”(2019ZX09721001-004-004) 

主　　题：patients al interferon 

摘      要：Recently,a paper published in Science by Hadjadj et *** that type I interferon(IFN)deficiency,could be a hallmark of severe coronavirus disease 2019(COVID-19)caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2).Severe COVID-19 was also associated with a lymphocytopenia,persistent blood viral load,and an exacerbated inflammatory response(Fig.1).These findings provide insights into the treatment of severe COVID-19 patients with type I IFN.